Evofem Biosciences, Inc., (OTCID: EVFM) is a San-Diego based pharmaceutical company commercializing two FDA-approved sexual and reproductive health products. In 2020, we launched PHEXX® (lactic acid, citric acid, and potassium bitartrate), the first and only hormone-free, on-demand prescription contraceptive vaginal gel. In 2024, Evofem acquired and re-launched SOLOSEC® (secnidazole) 2 g oral granules, an FDA-approved single-dose oral antibiotic for the treatment of bacterial vaginosis (BV) and trichomoniasis. Visit phexx.com and solosec.com to learn more and for important safety information.
Looking for a particular Evofem Biosciences employee's phone or email?
The Evofem Biosciences annual revenue was $17.7 million in 2026.
Saundra Pelletier is the CEO ► Phexxi ► Solosec of Evofem Biosciences.
35 people are employed at Evofem Biosciences.
Evofem Biosciences is based in San Diego, California.
The NAICS codes for Evofem Biosciences are [32541, 325, 32, 3254].
The SIC codes for Evofem Biosciences are [28, 283].